Low-dose abiraterone with food proves its worth in small Phase II trial

We have known for some time that taking abiraterone acetate (Zytiga) with food (as opposed to on an empty stomach) might well allow patients to be able to take significantly lower doses of this product and gain the same clinical benefit as is currently known to be beneficial from taking 1,000 mg/day when fasting. … READ MORE …

Lower dosing of abiraterone acetate in treatment of elderly prostate cancer patients

A group of Italian clinicians and researchers have reported that low-dose abiraterone acetate along with very low-dose prednisone appears to be both effective and safe in the treatment of elderly patients between 85 and 93 years of age with castration-resistant prostate cancer (CRPC). … READ MORE …

Abiraterone acetate and the “food effect”

For a while now there have been questions about whether taking abiraterone acetate with food as opposed to without food could be clinically beneficial for patients.

A new paper by Stover et al. has provided us with a little more information on this topic (but not a lot!).

Here in the USA, the manufacturer clearly states that

  • “No food should be eaten 2 hours before and 1 hour after taking [abiraterone];”
  • Abiraterone should be taken on an empty stomach; and
  • “Taking [abiraterone] with food may cause more of the medicine to be absorbed by the body than is needed and this may cause side effects.”

(We have added emphasis to the word “may” in this last sentence.)

In fact, what is known is that combining abiraterone acetate with food may (that word again) result in additional inhibition of enzymes involved in the androgen synthesis process association with progressive, castration-resistant prostate cancer (CRPC). This has two possible implications:

  • Some men may be able to use abiraterone acetate initially at lower doses if it is combined with food.
  • Some men who start to progress on a standard dose of abiraterone acetate may be able to take that standard dose with food and gain a clinical benefit (but at potential risk of an increase in side effects).

So let’s be very clear:

  • Neither of these things should be done by any patient without an initial discussion with his doctor.
  • Starting on the standard dose of abiraterone acetate and taking it with food is probably not a very good idea, because if you are one of those patients at significant risk for side effects to this drug, you are going to make that risk significantly worse!

Having said that, let’s look at what Stover et al. did and learned.

They carried out chart reviews on a total of 60 men with metastatic CRPC who were treated with abiraterone between April 1, 2011 and December 31. Of these 60 men, 19 switched from taking abiraterone without food to taking it with food at the time of their initial PSA progression on abiraterone during the study period.

Here is what the authors found:

  • Among the 19 men who switched administration from without food to with food,
    • 14/19 patients (74 percent) had previously had an initial response to abiraterone when taking it without food.
    • 3/19 patients (16 percent) had a PSA decrease within 3 months when taking abiraterone with food.
    • All three responders to the switch had been initial responders to abiraterone when taking it without food
    • Testosterone levels declined in 5/7 patients (71 percent) who switched to taking abiraterone with food.
  • Median time on abiraterone therapy for the 19 men who switched to taking abiraterone with food on initial progression was 100 days longer than among the 41 men who continued taking abiraterone without food.
  • There were no observable increases in toxicity of  abiraterone among the men taking with with food as compared to those taking it without.

Stover et al. reach a very basic conclusion:

Some men with mCRPC may benefit from taking AA with food.

And at the moment that may be the best that we can say.

Prospective trials are being conducted to investigate the food effects of abiraterone. One small trial with 25 patients has been completed (but not yet reported); another trial — with 72 patients — is ongoing. But what is certainly worth knowing is that if you are receiving treatment with abiraterone acetate for CRPC (without food at time of drug administration), and you have an in initial, meaningful PSA response to treatment, then when you show initial signs of PSA progression you may want to talk to your doctors about switching to taking the drug with food … but do talk to your doctor about this; don’t just do it on your own.

Taking abiraterone acetate with and without food: some new data

A new paper in the journal Prostate Cancer and Prostatic Diseases suggests that, at least for some men, disease progression while on abiraterone acetate may be (temporarily) reversible when they take the drug with food as opposed to without food (the latter being the standard recommendation). … READ MORE …

The two final sets of ASCO-related data (on a polyphenol-rich food supplement and curcuminoids)

Here is the last of our data-based reports from the annual meeting of the American Society for Clinical Oncology (ASCO), which ended last Tuesday. It deals with two presentations that are at least intellectually interesting but do not as yet “translate” into any type of clinical certainty. … READ MORE …

Of cow’s milk, doughnuts, fried chicken, and other important food groups

Two recent articles have linked certain dietary habits to risk for development of prostate cancer. The degree to which one feels that these dietary habits may be “proven” to increase risk for prostate cancer is probably going to be debatable; the existence of a potential link is certainly clear. … READ MORE …